Our study suggests that Ano1 expression in combination of clinical relevant markers ER, PR, HER2, and Ki67 is useful for predicting clinical outcomes of breast cancer patients, especially those with luminal A breast cancer, following tamoxifen treatment. This evidence concerns the gene ERBB2 and breast cancer.